Network Analysis Reveals Proteins Associated with Aortic Dilatation in Mucopolysaccharidoses

Overview

Journal Interdiscip Sci

Specialty Biology

Date 2021 Jan 21

PMID 33475959

Citations 1

Authors

Thiago Correa

Bruno Cesar Feltes

Esteban Alberto Gonzalez

Guilherme Baldo

Ursula Matte

Affiliations

Soon will be listed here.

Abstract

Mucopolysaccharidoses are caused by a deficiency of enzymes involved in the degradation of glycosaminoglycans. Heart diseases are a significant cause of morbidity and mortality in MPS patients, even in conditions in which enzyme replacement therapy is available. In this sense, cardiovascular manifestations, such as heart hypertrophy, cardiac function reduction, increased left ventricular chamber, and aortic dilatation, are among the most frequent. However, the downstream events which influence the heart dilatation process are unclear. Here, we employed systems biology tools together with transcriptomic data to investigate new elements that may be involved in aortic dilatation in Mucopolysaccharidoses syndrome. We identified candidate genes involved in biological processes related to inflammatory responses, deposition of collagen, and lipid accumulation in the cardiovascular system that may be involved in aortic dilatation in the Mucopolysaccharidoses I and VII. Furthermore, we investigated the molecular mechanisms of losartan treatment in Mucopolysaccharidoses I mice to underscore how this drug acts to prevent aortic dilation. Our data indicate that the association between the TGF-b signaling pathway, Fos, and Col1a1 proteins can play an essential role in aortic dilation's pathophysiology and its subsequent improvement by losartan treatment.

Citing Articles

Improving the response to lenvatinib in partial responders using a Constrained-Disorder-Principle-based second-generation artificial intelligence-therapeutic regimen: a proof-of-concept open-labeled clinical trial.

Sigawi T, Gelman R, Maimon O, Yossef A, Hemed N, Agus S Front Oncol. 2024; 14:1426426.

PMID: 39139285 PMC: 11319816. DOI: 10.3389/fonc.2024.1426426.

References

Giugliani R . Mucopolysacccharidoses: From understanding to treatment, a century of discoveries. Genet Mol Biol. 2013; 35(4 (suppl)):924-31. PMC: 3571427. DOI: 10.1590/s1415-47572012000600006. View

Stapleton M, Arunkumar N, Kubaski F, Mason R, Tadao O, Tomatsu S . Clinical presentation and diagnosis of mucopolysaccharidoses. Mol Genet Metab. 2018; 125(1-2):4-17. DOI: 10.1016/j.ymgme.2018.01.003. View

Stapleton M, Hoshina H, Sawamoto K, Kubaski F, Mason R, Mackenzie W . Critical review of current MPS guidelines and management. Mol Genet Metab. 2018; 126(3):238-245. DOI: 10.1016/j.ymgme.2018.07.001. View

Matte U, Yogalingam G, Brooks D, Leistner S, Schwartz I, Lima L . Identification and characterization of 13 new mutations in mucopolysaccharidosis type I patients. Mol Genet Metab. 2003; 78(1):37-43. DOI: 10.1016/s1096-7192(02)00200-7. View

Yogalingam G, Guo X, Muller V, Brooks D, Clements P, Kakkis E . Identification and molecular characterization of alpha-L-iduronidase mutations present in mucopolysaccharidosis type I patients undergoing enzyme replacement therapy. Hum Mutat. 2004; 24(3):199-207. DOI: 10.1002/humu.20081. View

Pollard L, Jones J, Wood T . Molecular characterization of 355 mucopolysaccharidosis patients reveals 104 novel mutations. J Inherit Metab Dis. 2012; 36(2):179-87. DOI: 10.1007/s10545-012-9533-7. View

Lin H, Lin S, Chuang C, Chen M, Chen B, Wraith J . Mucopolysaccharidosis I under enzyme replacement therapy with laronidase--a mortality case with autopsy report. J Inherit Metab Dis. 2006; 28(6):1146-8. DOI: 10.1007/s10545-005-0211-x. View

Martins A . Introduction to Brazilian Guidelines to Diagnosis, Treatment,and Monitoring for Gaucher Disease, Fabry Disease, Mucopolysaccharidosis I, and Pompe Disease. J Pediatr. 2009; 155(4 Suppl):S9. DOI: 10.1016/j.jpeds.2009.07.007. View

Imundo L, LeDuc C, Guha S, Brown M, Perino G, Gushulak L . A complete deficiency of Hyaluronoglucosaminidase 1 (HYAL1) presenting as familial juvenile idiopathic arthritis. J Inherit Metab Dis. 2011; 34(5):1013-22. DOI: 10.1007/s10545-011-9343-3. View

10.

de Oliveira Poswar F, de Souza C, Giugliani R, Baldo G . Aortic root dilatation in patients with mucopolysaccharidoses and the impact of enzyme replacement therapy. Heart Vessels. 2018; 34(2):290-295. DOI: 10.1007/s00380-018-1242-1. View

11.

Braunlin E, Harmatz P, Scarpa M, Furlanetto B, Kampmann C, Loehr J . Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management. J Inherit Metab Dis. 2011; 34(6):1183-97. PMC: 3228957. DOI: 10.1007/s10545-011-9359-8. View

12.

Bigg P, Baldo G, Sleeper M, ODonnell P, Bai H, Rokkam V . Pathogenesis of mitral valve disease in mucopolysaccharidosis VII dogs. Mol Genet Metab. 2013; 110(3):319-28. PMC: 3800211. DOI: 10.1016/j.ymgme.2013.06.013. View

13.

Baldo G, Tavares A, Gonzalez E, Poletto E, Mayer F, Matte U . Progressive heart disease in mucopolysaccharidosis type I mice may be mediated by increased cathepsin B activity. Cardiovasc Pathol. 2017; 27:45-50. DOI: 10.1016/j.carpath.2017.01.001. View

14.

Simonaro C, DAngelo M, He X, Eliyahu E, Shtraizent N, Haskins M . Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am J Pathol. 2007; 172(1):112-22. PMC: 2189614. DOI: 10.2353/ajpath.2008.070564. View

15.

Ausseil J, Desmaris N, Bigou S, Attali R, Corbineau S, Vitry S . Early neurodegeneration progresses independently of microglial activation by heparan sulfate in the brain of mucopolysaccharidosis IIIB mice. PLoS One. 2008; 3(5):e2296. PMC: 2396504. DOI: 10.1371/journal.pone.0002296. View

16.

Baldo G, Wu S, Howe R, Ramamoothy M, Knutsen R, Fang J . Pathogenesis of aortic dilatation in mucopolysaccharidosis VII mice may involve complement activation. Mol Genet Metab. 2011; 104(4):608-19. PMC: 3283036. DOI: 10.1016/j.ymgme.2011.08.018. View

17.

Ma X, Tittiger M, Knutsen R, Kovacs A, Schaller L, Mecham R . Upregulation of elastase proteins results in aortic dilatation in mucopolysaccharidosis I mice. Mol Genet Metab. 2008; 94(3):298-304. PMC: 3775334. DOI: 10.1016/j.ymgme.2008.03.018. View

18.

Gonzalez E, Tavares A, Poletto E, Giugliani R, Matte U, Baldo G . Losartan improves aortic dilatation and cardiovascular disease in mucopolysaccharidosis I. J Inherit Metab Dis. 2017; 40(3):311-312. DOI: 10.1007/s10545-017-0014-x. View

19.

Du P, Kibbe W, Lin S . lumi: a pipeline for processing Illumina microarray. Bioinformatics. 2008; 24(13):1547-8. DOI: 10.1093/bioinformatics/btn224. View

20.

Dunning M, Smith M, Ritchie M, Tavare S . beadarray: R classes and methods for Illumina bead-based data. Bioinformatics. 2007; 23(16):2183-4. DOI: 10.1093/bioinformatics/btm311. View